Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
65–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 65 years
Sitting systolic blood pressure (SBP) ≥ 160 mmHg and any diastolic blood pressure (DBP) (safety maximum of sitting DBP 110 mmHg), measured by manual cuff sphygmomanometer at the end of the wash-out period
Written informed consent
You may not be if
Secondary hypertension
Malignant hypertension (retinal haemorrhage, exudates or papillary oedema)
Clinically significant sodium depletion as defined by serum sodium level \< 130 mEq/L, clinically significant hyperkaliemia as defined by serum potassium level \> 5.5 mEq/L, clinically significant hypokaliemia as defined by serum potassium level \< 3.0 mEq/L
Atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which could interfere with the cardiac rhythm
Heart rate \< 50 bpm
Congestive heart failure (CHF) (NYHA (New York Heart Association) functional class CHF III-IV)
Angina pectoris or myocardial infarction
Cardiac surgery within the past 3 months prior to start the wash-out period
Stroke within the past 6 months prior to start the wash-out period
Renal insufficiency defined as creatininaemia \> 2mg/dl
Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post renal transplant
Liver insufficiency, defined as bilirubinaemia \> 2mg/dl and AST (aspartate aminotransferase) or ALT (alanine-aminotransferase) \> twice the upper normal range
Clinically significant metabolic and endocrine disease
Autoimmune disease
Previous history of angioedema
Body mass index \> 30kg/m2
Arm circumference \> 32 cm
Any condition that may be likely to compromise the trial (alcohol or drug abuse, disability illness, etc.)
Concomitant therapy with antihypertensive drugs non-permitted by protocol, or present use of tricyclic antidepressant, corticosteroids or drugs known to affect blood pressure
Investigational drug treatment within the past 30 days before the enrolment or concurrent participation to any other trial
Sensitivity, significant adverse reaction or contraindications to the study drugs (telmisartan, enalapril, clonidine TTS)
Predictable lack of patient co-operation
Clareo Health | Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension
